Zydus Cadila has received final USFDA approval to market Doxycycline Hyclate delayed-release tablets which are used to treat bacterial infections.
The drug will be marketed in the strengths of 75 mg, 100 mg and 150 mg and will be produced in its manufacturing facility in Ahmedabad. The group has also received tentative approval for Febuxostat tablets in the strengths of 40 mg and 80 mg which are used to treat hyperuricemia (constantly high levels of uric acid) in adults who have gout.
Company Profile : Cadila Healthcare Ltd
Leave a Reply